The price sensitive component is the mouse AML data that was published in the journal Blood. While many people here have read this already, for most shareholders it is new.
What makes it price sensitive is the results are statistically significant. The rule the ASX uses to determine price sensitive preclinical announcements from non-price sensitive announcements is the p-value. A p-value of less than 0.05 is price sensitive, while no p-value and the announcement is not price sensitive. As a scientist this doesn't make much sense to me, but such is the world we live in.
Having said all this the mouse data is really exciting and very relevant for the upcoming AML Phase 1/2 trial. If low dose bisantrene + decitabine performs even half as well in humans as in the mouse studies we will have a major winner on our hands.
Ann: December 2023 Preclinical & Clinical Program Update, page-7
-
- There are more pages in this discussion • 60 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.70 |
Change
-0.140(7.61%) |
Mkt cap ! $289.4M | |||
| Open | High | Low | Value | Volume |
| $1.88 | $1.89 | $1.70 | $456.4K | 259.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $1.69 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.70 | 8662 | 1 |
View Market Depth
| Last trade - 16.10pm 24/06/2024 (20 minute delay) ? |
| RAC (ASX) Chart |